Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis

Daewoong Pharmaceutical

Status and phase: Terminated; Phase 3

Conditions: Gastritis

Treatments: Drug: placebo of DWC20156; Drug: DWC20156; Drug: DWC20155; Drug: placebo of DWC20155

Study type: Interventional

Funder types: Industry

Identifiers

NCT03184415

DW_DWJ1366006

Details and patient eligibility

About

THe purpose of this study is to evaludate the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients with Gastritis

Enrollment: 230 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male of female of at least 19 years old
• Patients diagnosed with acute or chronic gastritis by gastroscopy
• Patients with one or more erosions found by gastroscopy

Exclusion criteria

• Patients with peptic ulcer and gastroesophageal reflux disease
• Patients with previous gastrointestinal surgery
• Patients with history of gastrointestinal cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

230 participants in 3 patient groups

DWC20155/DWC20156 Combination Therapy

Experimental group

Treatment:

Drug: placebo of DWC20155

Drug: DWC20156

Drug: DWC20155

DWC20155 Monotherapy

Active Comparator group

Treatment:

Drug: placebo of DWC20155

Drug: DWC20155

Drug: placebo of DWC20156

DWC20156 Monotherapy

Active Comparator group

Treatment:

Drug: placebo of DWC20155

Drug: DWC20156